Lung Non-Small Cell Carcinoma Clinical Trials in Seattle, Washington

6 studies are recruiting for lung non-small cell carcinoma in Seattle, Washington right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

   This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may in…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Swedish Medical Center-First Hill, Seattle, Washington

   Locations

   279 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT06498635 on ClinicalTrials.gov

2. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

   This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immu…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Pacific Gynecology Specialists, Seattle, Washington

   Locations

   1151 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT04267848 on ClinicalTrials.gov

3. A Multiple Antigen Vaccine (STEMVAC) for the Treatment of Patients With Stage IV Non-Small Cell Lung Cancer

   This phase II trial tests whether CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope plasmid DNA vaccine (STEMVAC) works to shrink tumors in patients with stage IV non-small cell lung cancer. STEMVAC targets specific immunogenic proteins that help lung cancer cells to grow. STEMVAC is made up of deoxyribonuclei…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Locations

   2 in total

   Run by

   University of Washington

   See if you can join NCT05242965 on ClinicalTrials.gov

4. Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial

   This clinical trial studies how well exercise training works in improving immune activity and treatment tolerance and response in patients with non-small cell lung cancer (NSCLC) who are receiving immunotherapy. Immunotherapy may induce changes in the body's immune system and may interfere with the…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington

   Run by

   Fred Hutchinson Cancer Center

   See if you can join NCT06983899 on ClinicalTrials.gov

5. Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

   This phase II Expanded Lung-MAP treatment trial tests how well amivantamab-subcutaneous (SC) works in treating patients patients with MET amplification non-small cell lung cancer. Amivantamab-SC is a drug that reduces extra copies of the MET gene, a change present in your tumor. Giving amivantamab-…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Swedish Medical Center-First Hill, Seattle, Washington

   Locations

   248 in total

   Run by

   SWOG Cancer Research Network

   See if you can join NCT06116682 on ClinicalTrials.gov

6. Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

   This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies with chemotherapy and/or (immune checkpoint inhibitors) ICIs.

   Stage

   Not phased

   Ages

   18 and older

   Site

   Kaiser Permanente Washington, Seattle, Washington

   Locations

   467 in total

   Run by

   Wake Forest University Health Sciences

   See if you can join NCT06418204 on ClinicalTrials.gov